Learning outcomes
By the end of this lesson you should be able to: define the therapeutic window and relate it to monitoring; outline the phases of drug development and what each is designed to answer; identify the point in the sequence at which a drug becomes available to patients; describe how generic substitution differs from brand prescribing; state the requirements for safe prescribing — indication, dose, route, duration, monitoring, and the review of interactions; and define an adverse drug reaction and give the four categories.
Prerequisites
Lessons 1-4, and the concept of therapeutic drug monitoring. This lesson applies the preceding principles to prescribing practice.
The big idea
Therapeutic index is the ratio of the dose that produces toxicity to the dose that produces the desired effect in half the population. Most drugs have a wide index, and they can be given with confidence. A few — digoxin, lithium, phenytoin, warfarin, aminoglycosides, and the anticancer drugs — have a narrow index, and they are monitored by blood concentration because the consequence of exceeding the window is severe.
Worked example: therapeutic drug monitoring
| Drug | Why it is monitored | Target range | Timing of the sample |
|---|---|---|---|
| Digoxin | Narrow index, and toxicity is additive with a low potassium | About 0.5 to 2.0 micrograms per litre | At least 6 to 12 hours after the last dose, because of the distribution phase |
| Lithium | Narrow index, with tinnitus and tremor as early toxicity | About 0.6 to 1.0 millimoles per litre | 12 hours after the last dose, the trough, at steady state |
| Phenytoin | Zero-order kinetics, and enzyme induction changes it | About 10 to 20 milligrams per litre | Any time after the distribution phase, but interpreted with the dose and other drugs |
| Aminoglycosides (gentamicin) | Toxicity to the ear and kidney, and clearance depends on renal function | Peak and trough targets quoted by the laboratory | Trough immediately before the next dose |
Two rules apply to every monitoring decision. The blood level is meaningless before the drug has reached steady state — at least four to five half-lives after the last dose change. And it is meaningless unless the timing of the sample is known: a peak level taken at the wrong time will be interpreted wrongly. For this reason a trough sample is usually preferred, taken immediately before the next dose.
The phases of drug development
| Phase | Who participates | What the phase answers |
|---|---|---|
| Preclinical | Laboratory and animal studies | The biological activity and the early toxicity profile — but animal results predict human outcomes poorly |
| Phase I | 20 to 100 healthy volunteers | Safety, tolerability and the pharmacokinetic profile in humans, including the effect of food and dose proportionality |
| Phase II | 100 to 300 patients with the target disease | Efficacy at a defined dose range, and the identification of dose-limiting toxicities |
| Phase III | 1000 to 3000 patients, in randomised controlled trials against placebo or an established treatment | Comparative efficacy and safety, and the safety profile at a scale that might detect uncommon reactions |
| Phase IV (post-marketing) | All users after marketing approval | The detection of rare adverse effects, long-term safety, and unusual use — an active role, not a passive one |
A drug is approved on the basis of demonstrated efficacy, the demonstrated safety profile, and the quality of its manufacture, judged against the balance of benefit and risk. Approval means that the manufacturer may market it for a defined indication, at defined doses, in a defined population. It does not mean the drug is free of all risk, and it does not mean a new indication is covered — which is why prescribing outside the approved indication (off-label use) is common, and explicitly documented, in paediatrics and in psychiatry.
Why is a rare but serious adverse effect often discovered only after a drug is marketed?
Prescribing and safety
A prescription carries a minimum set of information: the patient, the drug by generic name, the dose and its units, the route, the frequency, the duration, and the indication. A safe prescription also records the monitoring that is needed and the reason for any deviation from a standard choice.
| Category | Definition | Example |
|---|---|---|
| Type A (predictable) | A drug's known pharmacology, exaggerated by dose or by individual sensitivity | Hypotension from an antihypertensive; hypoglycaemia from insulin |
| Type B (idiosyncratic) | An unpredictable reaction, often immune-mediated and not dose-related | Anaphylaxis to penicillin; agranulocytosis with clozapine |
| Type C (chronic) | The effect of long-term exposure | Peptic ulceration from long-course NSAID use; osteoporosis from long-course corticosteroids |
| Type D (delayed) | A delayed consequence, including teratogenicity and carcinogenicity | Vaginal adenocarcinoma with diethylstilboestrol; teratogenicity with thalidomide |
The value of the classification is that it predicts what you should do about a reaction. Type A reactions stop when the dose stops, and a lower dose often suffices — they are the commonest. Type B reactions cannot be predicted, so the only safe advice is to avoid re-exposure and to report them, so that the pattern becomes visible. Types C and D need long-term monitoring and a programme of follow-up, because their consequences only emerge later.
Common mistakes
Watch outSaying a drug level can be taken any time after starting. A level is only interpretable at steady state, at least four to five half-lives after the last dose change, and at a properly defined point in the dosing interval.
Watch outSaying Phase III trials detect all adverse effects. They detect common ones; rare and long-term effects are found in Phase IV pharmacovigilance after marketing.
Watch outSaying a generic drug is a different drug. Generic drugs contain the same active ingredient as the brand, and they are approved by demonstrating bioequivalence — they differ in inactive ingredients, excipients and appearance.
Check your understanding
What does therapeutic drug monitoring of digoxin mean, and why is the timing of the sample important?
Why is a post-marketing safety study needed after a randomised, controlled trial?
Which category of adverse drug reaction does not depend on the dose, and what is the practical consequence?
Multiple choice
Which drug class requires therapeutic drug monitoring because of a narrow therapeutic index?
What is the primary purpose of a Phase I clinical trial?
Which of these is an example of a type B (idiosyncratic) adverse drug reaction?
A patient's lithium level is taken two days after starting treatment. What is wrong with that plan?
Which describes the difference between a generic and a brand-name version of the same drug?
Summary and next
The therapeutic window decides whether a drug is monitored, and a narrow index is the reason for therapeutic drug monitoring, whose result is only interpretable at steady state and at a defined point in the dosing interval. Drug development proceeds through preclinical studies and four clinical phases, each answering a different question, with the detection of rare adverse reactions left to the post-marketing phase. Safe prescribing records the indication, dose, route, duration and monitoring, and adverse drug reactions are classified as type A, B, C and D, because the classification dictates the response.
Next module: autonomic pharmacology, where the two branches of the autonomic nervous system are examined through their receptors and the drugs that act on them — and where almost every class you will meet in later systems has already made its first appearance.